Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.

Sepmeyer, Jacob A; Greer, John P; Koyama, Tatsuki; Zic, John A

Sepmeyer, Jacob A; Greer, John P; Koyama, Tatsuki; Zic, John A.

Affiliation

Sepmeyer JA; Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-5227, USA

J Am Acad Dermatol ; 56(4): 584-7, 2007 Apr.

Article in En | MEDLINE | ID: mdl-17184879

Subject(s)

Lymphoma, T-Cell, Cutaneous/drug therapy; Lymphoma, T-Cell, Cutaneous/pathology; Tetrahydronaphthalenes/administration & dosage; Thiazolidinediones/administration & dosage; Aged; Anticarcinogenic Agents/administration & dosage; Bexarotene; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous/mortality; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Risk Assessment; Rosiglitazone; Single-Blind Method; Survival Analysis; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Tetrahydronaphthalenes / Lymphoma, T-Cell, Cutaneous / Thiazolidinediones Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Am Acad Dermatol Year: 2007 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links